Leukopaks

Immune cell availability can be a limiting factor in many areas of life science research. Leukopaks address this challenge by providing large, well-defined populations of peripheral blood mononuclear cells (PBMCs). Widely used across immunology, drug discovery, and cell therapy development, leukopaks enable researchers to run scalable, reproducible experiments that would otherwise require multiple donors and collections.

A leukopak is a highly concentrated preparation of white blood cells collected using a specialised procedure known as leukapheresis. This method yields substantial quantities of PBMCs, including T lymphocytes, B lymphocytes, and natural killer (NK) cells, from a single donor.

Overview of the collection process:

• Leukapheresis workflow: Whole blood is circulated through an apheresis device that separates blood components according to density. Leukocytes are retained, while the remaining components are safely returned to the donor. The procedure typically lasts several hours and allows the donor’s full blood volume to be processed multiple times.
• Cellular makeup: A standard leukopak generally contains at least 10 billion mononuclear cells (MNCs), a category of white blood cells characterised by a single nucleus and comprising T cells, B cells, and NK cells.

Leukopaks offer a number of practical and scientific advantages that make them particularly suited to immunology, cell therapy, and pharmaceutical research workflows.

1. A foundational input for cell therapy manufacturing

Leukopaks are a critical starting material for many advanced cell-based therapies, such as CAR‑T and TCR therapies used in oncology. Key benefits include:

• Abundant immune cells: High numbers of PBMCs, including therapeutically relevant T cells and NK cells, support downstream processes such as genetic engineering, expansion, and differentiation.
• Batch-to-batch consistency: Leukopaks sourced from healthy, well-characterised donors enable reproducible manufacturing, an essential requirement for scale-up and clinical translation.

2. Well suited for immunogenicity studies and drug discovery

For discovery and preclinical research, leukopaks offer several methodological advantages:

• Sufficient material for multiple assays: A single leukopak can supply enough cells to support repeated experiments from the same collection timepoint.
• Reduced biological variation: Working with cells from a single donor limits donor-to-donor variability, improving data reliability.
• Reproducible screening: This consistency is especially beneficial for longitudinal studies and high‑throughput drug screening programmes.

3. Improved scalability and experimental flexibility

When compared with other blood-derived materials such as buffy coats, leukopaks are better suited to large‑scale research needs. Excess material can be cryopreserved and used at later timepoints, allowing researchers to maintain continuity across experiments and reduce the need for additional collections.

Leukopaks may be the optimal choice if your work involves:

• Minimising donor variability: Essential for repeat studies and longitudinal experimental designs.
• High cell demand: Leukopaks provide large quantities of PBMCs in a single collection.
• Advanced research applications: Including cell therapy manufacturing, drug screening, and immunogenicity or safety assessments.

For these reasons, many research groups have transitioned to leukopaks for immunology and drug discovery projects, valuing their scalability, reproducibility, and logistical efficiency.

Leukopaks represent a robust and versatile source of PBMCs for life science research. By enabling access to large, consistent immune cell populations, they support a wide range of applications from early drug discovery to advanced cell therapy development. For researchers seeking to streamline workflows while maintaining experimental rigour, leukopaks offer a dependable solution with clear scientific and operational benefits.

Read the original blog post from Research Donors here.